RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to present significant findings from its Phase 3 RAISE trial on the treatment of refractory status epilepticus at the Neurocritical Care Society’s 22nd Annual Meeting in San Diego, from October 14-17. The company will also share insights from retrospective claims-based data concerning the management challenges of status epilepticus.
The main presentation is scheduled for October 17, 2024, at 9:35 a.m. PT, where Dr. Brandon Foreman of the University of Cincinnati will discuss the efficacy and safety of intravenous ganaxolone. This study, pivotal for its potential to change the treatment landscape for patients with refractory status epilepticus, is part of the Late-Breaking Science Oral Platform.
A poster presentation on October 16 at 2:45 p.m. PT will feature Dr. Henrikas Vaitkevicius from Marinus Pharmaceuticals, highlighting the high rate of interhospital transfers in status epilepticus cases. This session aims to shed light on the logistical hurdles faced in managing such cases effectively.
These presentations are crucial as they highlight Marinus Pharmaceuticals’ effort to advance treatment options for neurological conditions. The data on ganaxolone could potentially offer new hope for better management of refractory status epilepticus, a condition that remains a critical challenge in neurocritical care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.